The therapeutic potential of this mechanism has been demonstrated in OS models, where administration of synthetic TLR4 agonists reprogrammed M2 TAM to the M1 phenotype, leading to tumor regression and inhibition of metastasis [77]. Here, TLR4 is linked to neoplasm.